Date,Headline,Sentiment,Stock Symbol,Open,High,Low,Close,Volume,Dividends,Stock Splits,Price Increase
2024-09-20,"Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders",0.0,ONCO,4.639999866,4.639999866,3.200000048,3.279999971,133798,0,0.0,1
2024-07-15,Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds,-0.4767,ONCO,6.360000134,6.360000134,5.800000191,5.880000114,15883,0,0.0,1
2024-07-11,Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds,-0.4767,ONCO,5.840000153,6.0,5.639999866,5.760000229,30608,0,0.0,0
2024-05-30,Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday,-0.3818,ONCO,11.23999977,12.80000019,9.359999657,9.520000458,399008,0,0.0,1
2024-05-21,ONCO Stock Earnings: Onconetix Reported Results for Q1 2024,0.0,ONCO,6.239999771,6.239999771,5.199999809,5.360000134,32710,0,0.0,1
2024-02-13,Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors,0.0,ONCO,6.440000057,6.920000076,6.440000057,6.880000114,20045,0,0.0,1
2023-12-19,Onconetix  Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders,0.0,ONCO,9.199999809,9.199999809,8.0,8.0,14448,0,0.0,1
2023-12-18,Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix,0.0,ONCO,8.760000229,9.600000381,8.0,9.56000042,48773,0,0.0,1
2023-11-02,Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company,0.0,ONCO,15.60000038,16.84000015,15.11999989,15.92000008,24055,0,0.0,0
2023-11-01,Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1),0.0,ONCO,14.52000046,15.60000038,14.0,15.0,1428,0,0.0,1
2023-10-30,Blue Water Biotech Issues Letter to Shareholders,0.0,ONCO,13.0,14.80000019,12.92000008,13.19999981,1285,0,0.0,0
2023-10-10,Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO,0.0,ONCO,17.20000076,18.63999939,16.39999962,17.20000076,1543,0,0.0,1
2023-08-28,"Blue Water Biotech, Inc. Announces Notification From Nasdaq Related to Delayed Quarterly Report on Form 10-Q",-0.2263,ONCO,34.79999924,36.0,34.0,35.75999832,1483,0,0.0,1
2023-08-10,Blue Water Biotech and Copay Consultants Collaborate to Build Copay Assistance Programs for Blue Waters Commercial Products,0.0,ONCO,38.36000061,39.20000076,37.59999847,38.0,995,0,0.0,1
2023-08-03,Blue Water Biotech Announces Closing of Warrant Exercise and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds,-0.4767,ONCO,41.59999847,43.52000046,41.20000076,42.0,1070,0,0.0,1
2023-08-01,Blue Water Biotech Announces Exercise of Warrants and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds,-0.4767,ONCO,45.0,45.20000076,42.0,43.59999847,2328,0,0.0,1
2023-07-31,Blue Water Biotech and Knipper Health Join Forces to Distribute Samples for ENTADFI® and ZONTIVITY® to Physicians,0.296,ONCO,43.59999847,46.0,43.59999847,45.20000076,1980,0,0.0,1
2023-07-25,"Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®",0.5859,ONCO,45.20000076,45.20000076,42.79999924,43.59999847,3418,0,0.0,1
2023-07-17,Blue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch Activities,0.0,ONCO,48.0,48.0,45.0,46.0,1783,0,0.0,1
2023-07-11,Blue Water Biotech Teams with Advantage Point Solutions to Provide Healthcare Payer Coverage Support,0.6597,ONCO,45.59999847,48.0,45.59999847,48.0,2755,0,0.0,1
2023-07-06,Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for its FDA Approved Products,0.6249,ONCO,43.59999847,44.79999924,43.20000076,44.40000153,4240,0,0.0,0
2023-06-28,Monkeypox Vaccine: Blue Water Biotech Touts Encouraging Preclinical Data From Monkeypox Vaccine Candidate,0.5106,ONCO,47.20000076,47.59999847,46.0,46.79999924,3890,0,0.0,1
2023-06-21,Blue Water Biotech Collaborates with IQVIA to Build Medical Sales Representative Team to Market Commercial Product Portfolio,0.0,ONCO,49.20000076,51.59999847,47.59999847,50.0,8585,0,0.0,1
2023-06-15,Blue Water (BWV) Up on Acquisition of 6 FDA-Approved Drugs,0.0,ONCO,47.20000076,50.0,44.79999924,48.0,55608,0,0.0,1
2023-06-14,Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas,0.1027,ONCO,60.0,63.20000076,44.40000153,51.20000076,1439845,0,0.0,1
2023-05-12,Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights,0.0,ONCO,41.20000076,43.59999847,40.0,41.59999847,4550,0,0.0,0
2023-05-10,"Blue Water Biotech to Present Corporate Overview and ENTADFI® Launch Plan at the JMP Securities Life Sciences Conference in New York, NY",0.296,ONCO,40.79999924,41.20000076,40.0,41.20000076,2115,0,0.0,1
2023-04-26,"Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer",0.0,ONCO,41.59999847,44.79999924,41.59999847,43.20000076,9888,0,0.0,1
2023-04-25,Blue Water Biotech to Participate in the American Urological Association Annual Meeting 2023 to Promote Benign Prostatic Hyperplasia Treatment ENTADFI®,0.5994,ONCO,43.20000076,43.20000076,41.20000076,41.59999847,1865,0,0.0,1
2023-04-24,Blue Water Vaccines Announces Corporate Name Change to Blue Water Biotech in Connection with Transition into Commercial-Stage Biotechnology Company,0.0,ONCO,42.0,43.59999847,41.20000076,42.40000153,1623,0,0.0,1
2023-04-20,"Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset",0.5859,ONCO,44.0,45.20000076,42.79999924,42.79999924,7260,0,0.0,1
2023-04-12,"Blue Water Vaccines Announces Signing of Sponsored Research Agreement with The University of Texas Health Science Center at San Antonio to Initiate Non-Human Primate Study for Live Attenuated, Orally Delivered Chlamydia Vaccine",0.4939,ONCO,41.59999847,45.20000076,41.59999847,41.59999847,3125,0,0.0,1
2023-03-09,Blue Water Vaccines Reports Year 2022 Financial Results and Recent Business Highlights,0.0,ONCO,46.0,46.40000153,43.0,46.0,6885,0,0.0,0
2023-02-06,Blue Water Vaccines Appoints Seasoned Commercial Operations Leader Frank Jaeger as Senior Vice President of Marketing and Business Development,0.0,ONCO,49.20000076,51.20000076,49.20000076,50.40000153,2925,0,0.0,1
2023-02-01,Blue Water Vaccines Announces Partnership with AbVacc for Joint Development of Novel Monkeypox and Marburg Vaccine Candidates,0.3182,ONCO,48.0,52.0,46.95999908,50.0,20538,0,0.0,1
2023-01-17,Blue Water Vaccines Announces Appointment of Seasoned Public Market and Private Equity Investment Leader Timothy Ramdeen to Board of Directors,0.0,ONCO,48.79999924,50.0,46.40000153,47.20000076,5728,0,0.0,0
2023-01-09,Blue Water Vaccines to Present at Biotech Showcase 2023 During the 41st Annual J.P. Morgan Healthcare Conference Week in San Francisco,0.0,ONCO,46.40000153,48.0,45.59999847,45.79999924,3598,0,0.0,0
2022-12-12,"Blue Water Vaccines Announces Institutional Research Coverage by Two Notable Healthcare-Focused Wall Street Banks, Receives Buy Rating From Both",0.0,ONCO,49.59999847,53.59999847,48.52000046,52.0,11305,0,0.0,0
2022-12-06,Blue Water Vaccines Organizes Key Opinion Leader Event to Discuss Unmet Need for Acute Otitis Media and Pneumonia Vaccine and Its Streptococcus pneumoniae Vaccine Candidate,0.0,ONCO,52.79999924,52.79999924,44.59999847,46.40000153,8030,0,0.0,1
2022-12-01,"Blue Water Vaccines to Present Update on Novel, Live Attenuated, Intranasally Delivered Streptococcus pneumoniae Vaccine to Prevent Acute Otitis Media, Pneumococcal Pneumonia, and Invasive Pneumococcal Disease at the World Vaccine & Immunotherapy Congress West Coast 2022",0.34,ONCO,50.79999924,53.59999847,50.0,51.0,12798,0,0.0,0
2022-11-22,Fred Smith Co. turns quick $24M deal for Chatham quarry,0.0,ONCO,48.40000153,52.79999924,46.0,49.20000076,19960,0,0.0,0
2022-11-21,Blue Water Vaccines Shares Jump After Licensing Pact For Chlamydia Vaccine Candidate,0.296,ONCO,50.0,57.20000076,48.0,51.20000076,142278,0,0.0,1
2022-11-10,Blue Water Vaccines Reports Third Quarter 2022 Financial Results and Recent Business Highlights; Announces 5 Million Share Repurchase Program,0.296,ONCO,48.40000153,48.40000153,38.43999863,42.79999924,157328,0,0.0,1
2022-11-08,"Blue Water Vaccines Announces Appointment of Vuk Jeremi, Previous Chair of the Council of Europes Committee of Ministers and Previous President of the United Nations General Assembly, to Its Board of Directors",0.4215,ONCO,44.40000153,46.0,42.0,42.40000153,5910,0,0.0,0
2022-10-11,Blue Water Vaccines Announces Plans to Evaluate Efficacy of Streptococcus pneumoniae Vaccine Candidate Against Pneumococcal Pneumonia at the World Vaccine Congress in Barcelona,0.0,ONCO,67.19999695,72.40000153,60.79999924,63.59999847,54253,0,0.0,1
2022-09-21,Blue Water Vaccines to Present at World Vaccine Congress Europe 2022,0.0,ONCO,84.40000153,87.19999695,80.0,80.0,9045,0,0.0,1
2022-09-08,"Blue Water Vaccines to Present In Person and via Webcast at H.C. Wainwrights 24th Annual Global Investment Conference in New York, NY",0.0,ONCO,113.5999985,115.5599976,109.1999969,112.0,7503,0,0.0,0
2022-08-31,"Blue Water Vaccines to Present at H.C. Wainwrights 24th Annual Global Investment Conference in New York, NY",0.0,ONCO,121.1999969,130.0,119.1999969,126.0,29970,0,0.0,0
2022-08-24,"Blue Water Vaccines to Present at The Universal Influenza Vaccines 2022 Conference in Oxford, United Kingdom",0.4215,ONCO,129.6000061,140.8399963,125.5999985,130.0,31828,0,0.0,0
2022-08-22,Blue Water Vaccines Announces Appointment of Retired Deloitte Consulting Senior Managing Director Simon Tarsh to Board of Directors,0.0,ONCO,166.8000031,172.0,138.0,139.1999969,90510,0,0.0,1
2022-08-18,Blue Water Vaccines stock sinks after U.S. announces its own monkeypox vaccine plans,0.0,ONCO,205.6000061,251.1999969,165.1999969,171.3999939,573793,0,0.0,1
2022-08-17,"U.S. stocks end lower as investors weigh Fed minutes, retail sales",-0.296,ONCO,140.0,320.0,139.6000061,305.6000061,3851853,0,0.0,1
2022-08-16,7 Short-Squeeze Stocks to Put on Your Must-Watch List,0.0,ONCO,97.59999847,105.5999985,94.80000305,102.0,23960,0,0.0,1
2022-08-15,Blue Water Vaccines Reports Second Quarter 2022 Financial Results and Recent Business Highlights,0.0,ONCO,95.19999695,101.1999969,92.40000153,97.59999847,22498,0,0.0,0
2022-08-11,Blue Water Vaccines Announces Closing of $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules,0.0,ONCO,98.80000305,103.1999969,95.19999695,96.0,8495,0,0.0,0
2022-08-09,Blue Water Vaccines Announces $10 Million Private Placement Priced At-the-Market under Nasdaq Rules,0.0,ONCO,97.59999847,100.8000031,94.40000153,99.59999847,9135,0,0.0,1
2022-07-20,Blue Water Vaccines Announces Signing of Sponsored Research Agreement with Cincinnati Childrens Hospital Medical Center for S&P Vaccine Platform Development,0.4939,ONCO,76.80000305,94.80000305,76.0,84.40000153,41913,0,0.0,1
2022-06-06,Blue Water Vaccines to Present at the JMP Securities Life Science Conference,0.296,ONCO,154.3999939,157.6000061,143.1999969,146.0,8540,0,0.0,1
2022-05-31,Blue Water Vaccines Announces Sponsored Research Agreement Amendment to Continue Funding Universal Influenza Vaccine Development at The University of Oxford,0.4939,ONCO,171.6000061,183.1999969,164.8000031,176.3999939,22783,0,0.0,1
2022-05-19,"Blue Water Vaccines Announces Collaboration with Instituto Butantan for the Development of BWV-101, a Universal Influenza Vaccine Candidate",0.0,ONCO,184.8000031,203.6000061,172.3999939,174.0,67785,0,0.0,1
2022-05-13,Blue Water Vaccines Reports First Quarter 2022 Financial Results and Recent Business Developments,0.0,ONCO,263.2000122,292.0,220.8000031,226.3999939,166563,0,0.0,1
2022-05-12,Blue Water Vaccines Inc. to Present at H.C. Wainwright Global Investment Conference,0.0,ONCO,256.7999878,286.0,235.0,268.3999939,517558,0,0.0,0
2022-05-11,Blue Water Vaccines Announces Expanded License Agreement with St. Jude Childrens Research Hospital for Novel Bacterial Vaccine Platform,0.6705,ONCO,208.8000031,273.6000061,206.0,240.3999939,646753,0,0.0,0
2022-04-27,"Tenon Medical, Ostin Technology Shares Rocket in Market Debuts",0.296,ONCO,168.0,183.6000061,160.0,162.3999939,31218,0,0.0,0
2022-04-21,"Blue Water Vaccines Presents New Data Supporting Universal Influenza Vaccine Candidate at the World Vaccine Congress 2022 in Washington, DC",0.4404,ONCO,224.8000031,234.8000031,190.3999939,202.0,34433,0,0.0,0
2022-04-20,Blue Water Vaccines Announces Closing of $8 Million Private Placement Priced At-the-Market Under Nasdaq Rules,0.0,ONCO,241.1999969,248.0,225.6000061,228.0,19595,0,0.0,1
2022-04-13,Blue Water Vaccines Announces $8 Million Private Placement Priced At-the-Market Under Nasdaq Rules,0.0,ONCO,276.0,286.0,240.8000031,247.1999969,35735,0,0.0,1
2022-04-11,Blue Water Vaccines Inc to Present at World Vaccine Congress Washington 2022,0.0,ONCO,384.0,391.6000061,320.3999939,322.0,47908,0,0.0,1
2022-04-08,"BioMed Leaders: Sunshine Biopharma, PharmaDrug, Blue Water Vaccines, and MedAvail; Visionary CEOs Advancing Healthcare, with Vaccines, Cancer Therapeutics, and Affordable Pharmaceuticals",0.296,ONCO,507.2000122,565.5999756,426.1199951,434.0,267898,0,0.0,1
2022-04-01,IPOs Had a Dismal Quarter. The Silent Spell Could Be Ending.,-0.6124,ONCO,2149.600098,2476.800049,2149.600098,2476.800049,405,0,0.0,1
2022-03-22,Blue Water Vaccines Announces Publication in Nano Research Supporting Novel S&P Vaccine Platform Versatility,0.6369,ONCO,1574.0,1858.800049,1520.0,1858.800049,643,0,0.0,1
2022-02-23,Blue Water Vaccines Announces Closing of Initial Public Offering,0.0,ONCO,1895.599976,2072.0,1302.0,1992.0,1478,0,0.0,1
2024-09-11,CNEY Receives Nasdaq Notifications Regarding Minimum Market Value of Publicly Held Shares Requirement,0.5574,CNEY,0.689999998,1.600000024,0.689999998,1.389999986,347476100,0,0.0,0
2024-06-03,CNEY Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency,0.0,CNEY,0.529999971,0.540000021,0.514999986,0.528999984,46700,0,0.0,0
2024-04-04,CN Energy Group. Inc. to Present at The Aegis Capital Corp 2024 Virtual Conference,0.2732,CNEY,1.139999986,1.269999981,1.139999986,1.230000019,69800,0,0.0,0
2024-04-02,"Steven Berman, CN Energy Group, is Featured in an Interview with SmallCapsDaily",0.2732,CNEY,1.090000033,1.220000029,1.049999952,1.159999967,174800,0,0.0,0
2024-03-15,CN Energy Group Receives Re-order from Water Purification Customer for its Activated Carbon,0.2732,CNEY,1.120000005,1.230000019,1.120000005,1.149999976,26800,0,0.0,0
2024-02-26,CN Energy Group Provides Preliminary Unaudited Financial Information for the First Three Months of Fiscal Year 2024 and Announces an Operations Update,0.2732,CNEY,1.429999948,1.539999962,1.429999948,1.440000057,133700,0,0.0,0
2024-02-21,Why Is CN Energy (CNEY) Stock Up 46% Today?,0.2732,CNEY,1.529999971,1.779999971,1.360000014,1.600000024,16234200,0,0.0,0
2024-02-16,CN Energy Group. Inc. Appoints Steven Berman as the Chief Executive Officer,0.2732,CNEY,1.399999976,1.5,1.320000052,1.401000023,326500,0,0.0,0
2024-02-15,CNEY Released Its Audited Financial Results for Fiscal Year 2023,0.0,CNEY,1.269999981,1.549999952,1.269999981,1.549999952,554300,0,0.0,0
2024-02-12,"CNEY Will Host a Conference Call on February 16, 2024",0.0,CNEY,1.340000033,1.370000005,1.210000038,1.245000005,161000,0,0.0,0
2024-02-02,CNEY Regains Compliance with Nasdaq Minimum Bid Price Requirement,0.0,CNEY,1.5,1.559999943,1.350000024,1.409999967,136700,0,0.0,0
2024-01-05,CN Energy Group. Inc. Announces Nasdaq Delisting Notification and Intends to Appeal,0.2732,CNEY,1.799999952,1.860000014,1.679999948,1.710000038,141693,0,0.0,0
2023-09-07,CN Energy Group Secures Activated Carbon Order for $1.64 Million,0.5267,CNEY,4.46999979,4.710000038,3.75,3.809999943,104400,0,0.0,0
2023-08-28,CN Energy Group. Inc. Files Financial Results for the First Six Months of Fiscal Year 2023,0.2732,CNEY,5.670000076,5.699999809,4.380000114,4.769999981,71240,0,0.0,0
2023-08-02,The 3 Best $1 Stocks to Buy Now: August 2023,0.6369,CNEY,5.760000229,5.849999905,5.460000038,5.760000229,25000,0,0.0,0
2023-07-24,CNEY Receives NASDAQ Minimum Bid Price Requirement Extension,0.0,CNEY,5.309999943,5.610000134,5.309999943,5.369999886,7357,0,0.0,0
2023-05-17,CNEY Awarded License Renewal to Process and Sell Wood Products; Expects to Enhance Operating Efficiencies,0.6486,CNEY,6.420000076,6.929999828,5.880000114,6.71999979,60363,0,0.0,0
2023-04-25,15 Cheap Growth Stocks to Buy,0.3818,CNEY,6.480000019,6.480000019,6.059999943,6.300000191,14253,0,0.0,0
2023-03-20,CNEY Wins a Large Activated Carbon Order,0.5719,CNEY,6.300000191,6.300000191,6.0,6.059999943,21387,0,0.0,0
2023-02-01,Aegis Capital Corp. Acted as Sole Bookrunner on a $10 Million Underwritten Public Offering for CN Energy Group Inc. (NASDAQ:CNEY),0.2732,CNEY,14.69999981,15.23999977,14.22000027,14.39999962,125477,0,0.0,0
2023-01-30,CNEY Announces Pricing of $10 Million Underwritten Public Offering,0.0,CNEY,18.29999924,20.34000015,16.5,17.67000008,542217,0,0.0,1
2023-01-27,CNEY Announces Proposed Underwritten Public Offering of Securities,0.296,CNEY,49.20000076,65.09999847,49.20000076,65.09999847,75113,0,0.0,0
2023-01-23,CN Energy Establishes its U.S. Headquarters to Expand Its Biochar and Wood-based Activated Carbon Businesses in Global Markets,0.5267,CNEY,27.62999916,36.90000153,27.60000038,36.59999847,36000,0,0.0,1
2023-01-17,CNEY Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency,0.0,CNEY,30.0,31.20000076,21.69000053,26.06999969,21400,0,0.0,1
2022-11-25,CN Energy Group. Inc. has Upgraded its 6G Gasification Reactors,0.2732,CNEY,49.79999924,52.79999924,41.40000153,49.20000076,46007,0,0.0,1
2022-11-14,CN Energy Group. Inc. Has Obtained the Permit to Directly Sell to Drinkable Water Markets,0.2732,CNEY,56.09999847,60.59999847,56.09999847,59.70000076,4643,0,0.0,0
2022-10-05,Are CN Energy Group. Inc.'s (NASDAQ:CNEY) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?,0.128,CNEY,62.84999847,65.55000305,57.59999847,63.59999847,1517,0,0.0,1
2022-08-25,Consumers Dont Have the Money to Spend: 10 Chinese Stocks at Risk as Orders Drop,-0.4939,CNEY,64.5,64.5,61.5,62.81999969,620,0,0.0,1
2022-06-28,The past one-year earnings decline for CN Energy Group (NASDAQ:CNEY) likely explains shareholders long-term losses,-0.1531,CNEY,68.09999847,68.09999847,59.09999847,67.19999695,590,0,0.0,0
2022-05-06,Returns On Capital Signal Tricky Times Ahead For CN Energy Group (NASDAQ:CNEY),0.128,CNEY,40.65000153,41.61000061,39.0,39.90000153,1010,0,0.0,1
2022-02-10,CN Energy Named High-Technology Enterprise,0.2732,CNEY,58.5,63.0,56.70000076,57.59999847,937,0,0.0,0
2022-01-31,CN Energy's Subsidiary Completes New Manufacturing Facility,0.0,CNEY,52.5,57.59999847,52.5,57.59999847,960,0,0.0,1
2022-01-24,CN Energy and Xujin Environmental Protection Enter Strategic Cooperation,0.2732,CNEY,54.90000153,54.90000153,46.74000168,50.09999847,2447,0,0.0,0
2022-01-18,CN Energy Signs Operation & Management Agreement; Enters Multi-Billion Dollar Pharmaceutical Excipients Market,0.6486,CNEY,63.90000153,67.19999695,60.59999847,67.19999695,14677,0,0.0,0
2024-09-23,Tonix Pharmaceuticals Announces Data Presentations on TNX-102 SL for Fibromyalgia at the 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PDDS 2024),0.3182,TNXP,0.140000001,0.140000001,0.129999995,0.129999995,17367000,0,0.0,0
2024-09-19,Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra to Treat Migraines,0.6705,TNXP,0.159999996,0.170000002,0.150000006,0.150000006,28045800,0,0.0,0
2024-09-18,"New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose Solution",0.7906,TNXP,0.150000006,0.150000006,0.140000001,0.150000006,9080000,0,0.0,0
2024-09-16,Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO's Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency,-0.3818,TNXP,0.159999996,0.159999996,0.150000006,0.150000006,12634800,0,0.0,0
2024-09-11,Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing,0.0,TNXP,0.150000006,0.159999996,0.140000001,0.150000006,16902700,0,0.0,0
2024-09-10,Tonix Pharmaceuticals Announces Appointment of Thomas Englese as Executive Vice President of Commercial Operations,0.0,TNXP,0.170000002,0.170000002,0.150000006,0.159999996,25302600,0,0.0,0
2024-09-09,Tonix Pharmaceuticals Presented Data on the Potential Mpox Vaccine TNX-801 in  Using Synthetic Biology to Battle Mpox  Talk at Immunology Symposium at the University of Alberta,-0.3818,TNXP,0.230000004,0.230000004,0.159999996,0.170000002,229465000,0,0.0,0
2024-09-06,Tonix Pharmaceuticals Launches National Awareness Campaign on the Impact of Gastroparesis or Stomach Paralysis on the Absorption of Oral Migraine Medications at PAINWeek,0.0,TNXP,0.159999996,0.159999996,0.129999995,0.140000001,17159900,0,0.0,0
2024-09-04,"As Research into Pain Accelerates, a Newly Recognized Type of Pain Comes to the Forefront - Tonix Targets it with FDA-Fast Track-Designated TNX-102 SL",-0.765,TNXP,0.170000002,0.170000002,0.159999996,0.159999996,14601700,0,0.0,0
2024-08-29,Tonix Pharmaceuticals Presented Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium (MHSRS),-0.4215,TNXP,0.300000012,0.310000002,0.230000004,0.25999999,24468900,0,0.0,0
2024-08-28,Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the 2024 Military Health System Research Symposium (MHSRS),0.0,TNXP,0.349999994,0.349999994,0.289999992,0.300000012,40174400,0,0.0,0
2024-08-26,Tonix Pharma Collaborates With World's Largest Vaccine Manufacturer For Mpox Vaccine,0.0,TNXP,0.439999998,0.460000008,0.370000005,0.370000005,132606500,0,0.0,0
2024-08-23,Modern Twist to Centuries-Old Smallpox Vaccine Poised to Combat Deadly Mpox Strain as WHO Declares Global Emergency,-0.4939,TNXP,0.349999994,0.370000005,0.340000004,0.340000004,39397200,0,0.0,0
2024-08-21,Tonix Pharmaceuticals Announces Oral Presentation and Three Poster Presentations at the 2024 Military Health System Research Symposium (MHSRS),0.0,TNXP,0.340000004,0.379999995,0.330000013,0.360000014,40430400,0,0.0,0
2024-08-20,Tonix initiates Phase II trial for emergency cocaine intoxication treatment,-0.3818,TNXP,0.460000008,0.49000001,0.370000005,0.379999995,41576300,0,0.0,0
2024-08-19,Tonix Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Highlights,0.0,TNXP,0.600000024,0.850000024,0.419999987,0.449999988,290466000,0,0.0,0
2024-08-16,"TNXP Stock Earnings: Tonix Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024",-0.4215,TNXP,0.469999999,0.550000012,0.400000006,0.449999988,78585900,0,0.0,0
2024-08-13,Tonix Pharmaceuticals to Present at the Summer 2024 Virtual Investor Summit,0.0,TNXP,0.519999981,0.519999981,0.479999989,0.49000001,768600,0,0.0,0
2024-08-12,"Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia, the Prototypic Nociplastic Pain Syndrome, at the IASP 2024 World Congress on Pain",-0.765,TNXP,0.49000001,0.519999981,0.479999989,0.50999999,852000,0,0.0,0
2024-08-06,Tonix Pharmaceuticals Announces Publication in Microorganisms of Technology that Expands Company's Capabilities in Generating Potential Therapeutic Fully Human Antibodies Against SARS-CoV-2 and Other Pathogens,0.1027,TNXP,0.460000008,0.49000001,0.449999988,0.460000008,772500,0,0.0,0
2024-08-01,FDA Recognizes Fibromyalgia as a 'Serious Condition' And Fast-Tracks New Drug Candidate,-0.0772,TNXP,0.519999981,0.550000012,0.5,0.50999999,1706100,0,0.0,0
2024-07-31,Tonix Pharmaceuticals Announces Potential Positive Impact of the U.S. National Academies (NASEM) New Definition of Long COVID on the Size of the Fibromyalgia Market for Tonmya,0.5574,TNXP,0.529999971,0.540000021,0.5,0.5,2158400,0,0.0,1
2024-07-30,Tonix Pharmaceuticals Announces Poster Presentation at the IASP 2024 World Congress on Pain,-0.5106,TNXP,0.569999993,0.579999983,0.550000012,0.569999993,1186000,0,0.0,0
2024-07-29,Tonix Pharmaceuticals Awarded Up to $34 Million U.S. Department of Defense Contract for Accelerated Development of Broad-Spectrum Antiviral Program,0.4939,TNXP,0.550000012,0.579999983,0.529999971,0.569999993,2017600,0,0.0,0
2024-07-25,Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected,0.743,TNXP,0.560000002,0.600000024,0.460000008,0.579999983,11279300,0,0.0,1
2024-07-24,"Beyond 'One Bug, One Drug' - Tonix Pharmaceuticals Secures Up To $34 Million In Funding From The U.S. Department Of Defense To Develop a Broad-Spectrum Antiviral",0.4215,TNXP,0.600000024,0.610000014,0.519999981,0.529999971,11647500,0,0.0,0
2024-07-22,7 Sorry Biotech Stocks Set to Make Investors Sad,-0.5267,TNXP,0.579999983,0.589999974,0.540000021,0.560000002,2065600,0,0.0,0
2024-07-19,Tonix Pharmaceuticals Awarded potential 34 million dollar Contract with U.S. Department of Defence,0.4767,TNXP,0.569999993,0.589999974,0.560000002,0.560000002,1448800,0,0.0,0
2024-07-18,Tonix Pharmaceuticals receives positive feedback from FDA on Tonmya for fibromyalgia management,0.5574,TNXP,0.600000024,0.610000014,0.560000002,0.569999993,2040200,0,0.0,1
2024-07-17,"Tonix Pharmaceuticals, Set to File an NDA for Tonmya for the Management of Fibromyalgia, is Planning Expected Launch in 2H 2025",0.0,TNXP,0.610000014,0.610000014,0.589999974,0.600000024,1894300,0,0.0,1
2024-07-10,Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering,0.0,TNXP,0.610000014,0.629999995,0.600000024,0.620000005,3258900,0,0.0,0
2024-07-09,Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering,0.0,TNXP,0.600000024,0.629999995,0.579999983,0.600000024,4285500,0,0.0,0
2024-07-08,Tonix Pharmaceuticals Announces Proposed Public Offering,0.0,TNXP,0.829999983,0.839999974,0.699999988,0.709999979,4514200,0,0.0,0
2024-07-01,Nano-Cap Tonix Pharmaceuticals Secures Large US Department of Defense Contract,0.4215,TNXP,0.709999979,0.75,0.670000017,0.730000019,9917000,0,0.0,1
2024-06-28,Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering,0.0,TNXP,0.709999979,0.720000029,0.660000026,0.699999988,1556700,0,0.0,1
2024-06-27,AMZN Stock Alert: Amazon Just Joined the $2 Trillion Club,0.4404,TNXP,0.620000005,0.720000029,0.600000024,0.689999998,8457500,0,0.0,0
2024-06-26,Tonix Pharmaceuticals Announces Proposed Public Offering,0.0,TNXP,1.25,1.25,1.120000005,1.129999995,2116600,0,0.0,0
2024-06-25,Tonix Pharmaceuticals Presents Vaccine Platform Data in Keynote Talk at the Vaccine Congress 2024,0.0,TNXP,1.200000048,1.299999952,1.200000048,1.25,492200,0,0.0,0
2024-06-21,7 F-Rated Penny Stocks to Avoid This June,-0.296,TNXP,1.350000024,1.370000005,1.279999971,1.299999952,873300,0,0.0,0
2024-06-20,Tonix Pharmaceuticals Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya  for the Management of Fibromyalgia,0.5574,TNXP,1.279999971,1.370000005,1.149999976,1.350000024,2933800,0,0.0,1
2024-06-18,Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024,0.7269,TNXP,1.129999995,1.25999999,1.080000043,1.220000029,1710300,0,0.0,0
2024-06-17,Tonix Pharmaceuticals Presented Poster of Tonmya  for the Management of Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2024,0.0,TNXP,1.149999976,1.190000057,1.120000005,1.120000005,1282400,0,0.0,1
2024-06-13,Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering,0.0,TNXP,1.139999986,1.149999976,1.080000043,1.090000033,2106200,0,0.0,1
2024-06-12,FedEx Layoffs 2024: What to Know About the Latest FDX Job Cuts,-0.296,TNXP,1.139999986,1.200000048,1.080000043,1.110000014,5182200,0,0.0,1
2024-06-11,Tonix Pharmaceuticals Announces Proposed Public Offering,0.0,TNXP,2.039999962,2.190000057,2.0,2.130000114,702700,0,0.0,0
2024-06-10,SOUN Stock Alert: SoundHound AI Pays Off Debt Early,-0.0772,TNXP,2.5,2.640000105,2.180000067,2.210000038,939200,0,0.03125,0
2024-06-06,Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split,0.0,TNXP,4.800000191,4.800000191,3.200000048,3.519999981,539625,0,0.0,1
2024-06-05,Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2024,0.0,TNXP,4.800000191,4.800000191,4.800000191,4.800000191,101866,0,0.0,0
2024-06-03,Tonix Pharmaceuticals Presented New Data on Tonmya  Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting,-0.1779,TNXP,5.440000057,5.440000057,5.119999886,5.119999886,61734,0,0.0,0
2024-05-30,Tonix Pharmaceuticals Announces Two Poster Presentations of TNX-102 SL (Sublingual Cyclobenzaprine HCl) at the ASCP Annual Meeting,0.0,TNXP,5.440000057,5.440000057,5.440000057,5.440000057,73447,0,0.0,0
2024-05-29,Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024,0.0,TNXP,5.440000057,5.760000229,5.440000057,5.440000057,58616,0,0.0,0
2024-05-28,Tonix Pharmaceuticals Announces Presentation at the 2024 BIO International Convention,0.0,TNXP,5.760000229,5.760000229,5.440000057,5.440000057,45378,0,0.0,1
2024-05-22,Tonix Pharmaceuticals to Deliver an Oral Presentation and Present Two Posters at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting,0.0,TNXP,6.079999924,6.400000095,6.079999924,6.079999924,60931,0,0.0,0
2024-05-21,Tonix Pharmaceuticals Announces Key Findings from Initial Phase of EVERSANA Market Opportunity Analysis for Tonmya  for the Management of Fibromyalgia,0.4215,TNXP,6.400000095,6.71999979,5.760000229,5.760000229,101559,0,0.0,1
2024-05-20,"TNXP Stock Earnings: Tonix Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024",-0.2263,TNXP,6.400000095,6.71999979,6.079999924,6.079999924,73428,0,0.0,1
2024-05-15,Tonix Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase,0.0,TNXP,5.760000229,6.079999924,5.760000229,5.760000229,31313,0,0.0,1
2024-05-13,Tonix Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Highlights,0.0,TNXP,5.440000057,5.760000229,5.440000057,5.440000057,47859,0,0.0,1
2024-04-29,"Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV",0.0,TNXP,5.440000057,5.760000229,5.440000057,5.760000229,75191,0,0.0,0
2024-04-24,Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase,0.0,TNXP,5.119999886,5.119999886,5.119999886,5.119999886,30941,0,0.0,1
2024-04-09,3 Biotech Stocks to Dump Before They Go to Zero,-0.3818,TNXP,5.760000229,6.079999924,5.760000229,6.079999924,80850,0,0.0,1
2024-04-01,Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights,0.0,TNXP,6.400000095,6.400000095,5.440000057,6.079999924,280775,0,0.0,0
2024-03-28,Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering,0.0,TNXP,10.56000042,10.88000011,5.440000057,6.079999924,685128,0,0.0,0
2024-03-25,Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome,0.0,TNXP,11.19999981,11.19999981,10.23999977,10.56000042,130178,0,0.0,1
2024-03-21,Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting,0.3182,TNXP,11.52000046,11.84000015,10.88000011,10.88000011,50263,0,0.0,1
2024-03-20,Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya  for the Management of Fibromyalgia,0.0,TNXP,11.52000046,11.84000015,10.56000042,11.52000046,54234,0,0.0,1
2024-03-19,"Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024",0.0,TNXP,11.19999981,11.84000015,10.88000011,11.19999981,60381,0,0.0,1
2024-03-12,Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring,0.0,TNXP,11.52000046,11.52000046,10.56000042,10.56000042,50900,0,0.0,1
2024-03-11,"Tonix Pharmaceuticals Reports Improvement in  Brain Fog,  in Fibromyalgia Patients Treated with Tonmya  in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgia",0.4588,TNXP,11.84000015,12.15999985,11.19999981,11.52000046,83134,0,0.0,1
2024-03-07,"New to The Street Announces TV Episode 560 with its Five Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV Tonight, Thursday, March 7, 2024, at 9:30 PM PT",0.0,TNXP,11.84000015,11.84000015,11.19999981,11.84000015,41856,0,0.0,1
2024-03-06,Tonix Pharmaceuticals Selects EVERSANA  to Support Launch Strategy and Commercialization Planning of Tonmya  for the Management of Fibromyalgia,0.4019,TNXP,11.84000015,11.84000015,11.52000046,11.84000015,20775,0,0.0,1
2024-03-05,Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans,0.3612,TNXP,11.84000015,12.15999985,11.52000046,11.52000046,33125,0,0.0,1
2024-02-29,Tonix Pharmaceuticals Announces Presentation at The 6th International Congress on Controversies in Fibromyalgia,0.0,TNXP,12.47999954,12.47999954,11.84000015,12.15999985,51816,0,0.0,1
2024-02-28,Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers,0.4019,TNXP,12.15999985,12.47999954,11.84000015,11.84000015,42272,0,0.0,0
2024-09-23,"Applied Digital Sets Fiscal First Quarter 2025 Earnings Conference Call for Wednesday, October 9, 2024 at 5:00 p.m. Eastern Time",0.0,APLD,6.130000114,6.869999886,6.025000095,6.699999809,15381500,0,0.0,1
2024-09-18,Applied Digital (APLD): A Top Data Center Stock for HPC and Cloud Innovations,0.2023,APLD,5.78000021,6.699999809,5.744999886,6.070000172,16947900,0,0.0,1
2024-09-05,Nvidia among investors in Applied Digital's funding round,0.0,APLD,4.989999771,5.710000038,4.25,5.369999886,149889900,0,0.0,1
2024-08-30,Applied Digital Issues $53.2 Million Convertible Preferred Stock to Advance HPC Data Center Project and Accelerate Growth,0.3818,APLD,3.880000114,3.880000114,3.339999914,3.650000095,12775300,0,0.0,0
2024-08-29,10 Best Multibagger Penny Stocks of 2025,0.6369,APLD,4.289999962,4.96999979,3.714999914,3.819999933,9606500,0,0.0,1
2024-08-28,Applied Digital Reports Fiscal Fourth Quarter and Full Year 2024 Results,0.0,APLD,4.760000229,4.78000021,4.25,4.409999847,6291600,0,0.0,0
2024-08-20,"2024 Gateway Conference to Feature AI, Blockchain, and Digital Infrastructure Track on September 5th",0.0,APLD,4.139999866,4.25,3.984999895,4.03000021,1990500,0,0.0,0
2024-08-14,Applied Digital Strengthens Security Leadership with Appointment of Industry Veteran Gary Smith,0.6597,APLD,3.930000067,4.050000191,3.734999895,3.839999914,2107900,0,0.0,1
2024-08-07,"Applied Digital Sets Fiscal Fourth Quarter and Full Year 2024 Conference Call for Wednesday, August 28, 2024, at 5:00 p.m. Eastern Time",0.0,APLD,4.28000021,4.320000172,3.880000114,3.900000095,3044800,0,0.0,1
2024-07-30,Applied Digital Secures Final $25 Million from Garden City Facility Sale,0.3182,APLD,4.25,4.34499979,3.930000067,3.980000019,4895400,0,0.0,1
2024-07-24,Applied Digital Appoints New Chief Revenue Officer to Drive Next Phase of Growth,0.3818,APLD,5.010000229,5.179999828,4.540999889,4.570000172,5869000,0,0.0,1
2024-07-10,Applied Digital Announces Appointment of Industry-Leader Chris Jackson as Senior Vice President of Operations,0.0,APLD,5.570000172,6.255000114,5.510000229,5.860000134,9511600,0,0.0,1
2024-06-07,"Applied Digital Secures Private Debt Facility of up to $200 million to Accelerate HPC Data Center Project in Ellendale, North Dakota",-0.0516,APLD,4.760000229,4.980000019,4.454999924,4.5,3319400,0,0.0,1
2024-05-29,Penny Stocks with Promise: 3 Sub-$5 Picks Poised for Explosive Growth,0.7096,APLD,4.539999962,4.650000095,4.230000019,4.329999924,2904900,0,0.0,0
2024-05-28,Data Center Investments Soar: 200% Rise Since 2016 and Projected 89% Increase by 2028,0.3182,APLD,4.650000095,4.650000095,4.375,4.619999886,3785900,0,0.0,0
2024-05-24,"Applied Digital Issues Unsecured Convertible Debenture to Advance HPC Data Center Project in Ellendale, North Dakota",-0.3818,APLD,4.210000038,4.670000076,4.190000057,4.610000134,3379900,0,0.0,0
2024-05-14,Wall Street Favorites: 3 Blockchain Stocks With Strong Buy Ratings for May 2024,0.7269,APLD,3.569999933,3.75999999,3.420000076,3.579999924,4472300,0,0.0,0
2024-05-08,Applied Digital Announces Upcoming Conference Participation,0.0,APLD,3.059999943,3.319999933,3.019999981,3.299999952,3200300,0,0.0,0
2024-05-07,3 Under-$5 Penny Stocks That Could Make You Millions,0.0,APLD,3.200000048,3.200000048,2.99000001,3.099999905,3658500,0,0.0,0
2024-05-03,Applied Digital Announces Appointment of Datacenter Industry Expert Todd Gale as Chief Development Officer,0.0,APLD,3.0,3.109999895,2.980000019,3.029999971,1431100,0,0.0,0
2024-05-02,Shhh! 3 Secret Metaverse Stocks Flying Below Wall Street's Radar,0.0,APLD,3.039999962,3.119999886,2.920000076,2.960000038,2101200,0,0.0,0
2024-04-30,Applied Digital Appoints Ella Benson to Board of Directors,0.0,APLD,2.720000029,2.75,2.680000067,2.704999924,1268400,0,0.0,0
2024-04-26,"3 Stocks to Buy if You Want to Turn Your $1,000 into $10,000 Within 2 Years",0.0772,APLD,3.0,3.09800005,2.845000029,2.940000057,3299800,0,0.0,1
2024-04-22,3 Blockchain Stocks to Buy Now: Q2 Edition,0.0,APLD,2.519999981,2.720000029,2.470000029,2.710000038,2704700,0,0.0,0
2024-04-16,Applied Digital Corporation (NASDAQ:APLD) Q3 2024 Earnings Call Transcript,0.0,APLD,2.50999999,2.529999971,2.390000105,2.450000048,4752700,0,0.0,0
2024-04-11,Applied Digital Reports Fiscal Third Quarter 2024 Results,0.0,APLD,3.019999981,3.069999933,2.829999924,3.069999933,7801700,0,0.0,0
2024-04-09,"Applied Digital Reschedules Fiscal Third Quarter 2024 Earnings Conference Call to Thursday, April 11, 2024 at 5:00 p.m. Eastern Time",0.0,APLD,3.099999905,3.109999895,2.789999962,2.849999905,6485500,0,0.0,0
2024-04-08,Wall Street Favorites: 3 Blockchain Stocks With Strong Buy Ratings for April 2024,0.7269,APLD,3.099999905,3.150000095,2.950000048,3.125,3934100,0,0.0,0
2024-04-01,"Applied Digital Issues $50 Million Unsecured Convertible Debenture to Advance HPC Data Center Project in Ellendale, North Dakota",-0.3818,APLD,4.25,4.320000172,4.025000095,4.110000134,3194200,0,0.0,0
2024-03-28,"Applied Digital Sets Fiscal Third Quarter 2024 Earnings Conference Call for Wednesday, April 10, 2024 at 9:00 a.m. Eastern Time",0.0,APLD,4.349999905,4.534999847,4.260000229,4.28000021,2181900,0,0.0,0
2024-03-26,11 Crypto Stocks with Biggest Upside,0.0,APLD,4.429999828,4.5,4.320000172,4.329999924,1612700,0,0.0,0
2024-03-19,Applied Digital Among First Cloud Service Providers to Use New NVIDIA Blackwell Platform,0.0,APLD,4.260000229,4.324999809,4.074999809,4.28000021,2479600,0,0.0,0
2024-03-15,Applied Digital Announces Agreement to Sell Garden City Campus to Marathon Digital Holdings,0.4939,APLD,4.380000114,4.630000114,4.320000172,4.5,6103500,0,0.0,1
2024-03-14,"Applied Digital Secures Contract with AI Customer, Together AI",0.3182,APLD,4.630000114,4.739999771,4.204999924,4.230000019,2682400,0,0.0,0
2024-03-11,"7 Growth Stocks That Could Turn $10,000 Into $500,000",0.3818,APLD,4.440000057,4.539999962,4.199999809,4.199999809,2322500,0,0.0,0
2024-03-08,Applied Digital Provides Update on Anchor Tenant at Ellendale HPC Facility,0.0,APLD,4.25,4.78000021,4.25,4.590000153,3781300,0,0.0,0
2024-03-05,Applied Digital Completes Financing for Jamestown HPC Data Center Campus,0.0,APLD,4.110000134,4.190000057,4.025000095,4.090000153,2070000,0,0.0,0
2024-02-22,Rachel H. Lee Elected to Applied Digital Board of Directors,0.0,APLD,4.579999924,4.599999905,4.320000172,4.329999924,4016600,0,0.0,1
2024-02-12,"Applied Digital Joins AI Alliance to Collaborate with Industry Leaders to Advance Open, Safe, and Responsible AI",0.6369,APLD,5.150000095,5.403999805,4.739999771,4.849999905,5632300,0,0.0,0
2024-02-09,Applied Digital Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm,-0.5994,APLD,5.170000076,5.289999962,5.014999866,5.275000095,3533400,0,0.0,0
2024-02-06,Applied Digital Secures Additional Financing,0.3182,APLD,4.340000153,4.739999771,4.28000021,4.679999828,3524100,0,0.0,1
2024-01-18,Applied Digital Corporation (NASDAQ:APLD) Q2 2024 Earnings Call Transcript,0.0,APLD,5.289999962,5.460000038,4.824999809,4.929999828,5269700,0,0.0,0
2024-01-16,Applied Digital Corp (APLD) Reports Fiscal Q2 2024 Results: Revenue Soars Amidst Net Loss,-0.3182,APLD,6.25,6.340000153,5.510000229,5.53000021,13293900,0,0.0,0
2024-01-03,"Applied Digital Sets Fiscal Second Quarter 2024 Earnings Conference Call for Tuesday, January 16, 2024 at 9:00 a.m. Eastern Time",0.0,APLD,6.630000114,7.059999943,6.360000134,6.840000153,3440200,0,0.0,0
2023-12-19,Applied Digital Announces Long-Term Supply Agreement with TerraForm Power,0.4939,APLD,6.78000021,7.300000191,6.400000095,6.760000229,4601400,0,0.0,0
2023-12-01,The 3 Best Web3 Stocks to Buy Before Everyone Else Does,0.6369,APLD,4.650000095,5.264999866,4.624000072,5.190000057,3545600,0,0.0,0
2023-11-28,"Applied Digital to Host Ribbon Cutting Ceremony at its 200-Megawatt Datacenter in Garden City, Texas",-0.128,APLD,4.599999905,4.949999809,4.579999924,4.829999924,3038000,0,0.0,0
2023-11-20,Why Applied Digital Stock Zoomed Nearly 9% Higher Today,0.0,APLD,4.090000153,4.449999809,4.090000153,4.389999866,3069200,0,0.0,0
2023-11-15,WEKA Partners with Applied Digital to Supercharge Its GPU Cloud for Generative AI Customers,0.0,APLD,4.389999866,4.690000057,4.289999962,4.320000172,2252300,0,0.0,0
2023-11-13,Applied Digital Announces Upcoming Investor Events,0.0,APLD,4.650000095,4.710000038,3.519999981,3.940000057,9196700,0,0.0,0
2023-10-31,"Applied Digital Announces Groundbreaking of High-Performance Computing Facility in Ellendale, North Dakota",0.0,APLD,4.610000134,4.940000057,4.5,4.880000114,2264800,0,0.0,0
2023-10-20,"Applied Digital Announces Energization of its 200-Megawatt Datacenter in Garden City, Texas",0.3818,APLD,5.0,5.034999847,4.65500021,4.690000057,4401700,0,0.0,1
2023-10-17,Long-Term Investors in Applied Digital Corporation (NASDAQ: APLD) shares should contact the Shareholders Foundation in connection with a Lawsuit,0.0772,APLD,5.239999771,5.559999943,5.201000214,5.460000038,2201500,0,0.0,0
2023-10-11,Applied Digital Corporation (NASDAQ:APLD) Q1 2024 Earnings Call Transcript,0.0,APLD,5.449999809,5.816999912,5.170000076,5.260000229,4551300,0,0.0,0
2023-10-09,Applied Digital Reports Fiscal First Quarter 2024 Financial Results,0.0,APLD,5.519999981,6.193999767,4.425000191,4.809999943,14208000,0,0.0,0
2023-10-06,"Applied Digital Corporation investors: Please contact the Portnoy Law Firm to recover your losses; October 11, 2023 deadline.",-0.1027,APLD,5.019999981,5.230000019,4.929999828,5.170000076,5334100,0,0.0,0
2023-10-02,"Applied Digital Corporation investors: Please contact the Portnoy Law Firm to recover your losses; October 11, 2023 deadline",-0.1027,APLD,6.25,6.570000172,6.070000172,6.130000114,3041100,0,0.0,0
2023-09-28,"Applied Digital Sets Fiscal First Quarter 2024 Earnings Conference Call for Monday, October 9, 2023 at 9:00 a.m. Eastern Time",0.0,APLD,6.099999905,6.519999981,5.96999979,6.329999924,3832500,0,0.0,0
2023-09-20,"Applied Digital to Host Investor Day on October 12, 2023",0.0,APLD,5.010000229,5.429999828,4.980000019,5.239999771,3530700,0,0.0,0
2023-09-11,Applied Digital Announces Upcoming Investor Events,0.0,APLD,5.179999828,5.329999924,4.820000172,5.210000038,3503900,0,0.0,0
2023-09-01,"SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Applied Digital Corporation with Losses of $100,000 to Contact the Firm",0.4824,APLD,6.070000172,6.198999882,5.75,5.78000021,2106500,0,0.0,1
2023-08-29,Flexential Empowers Applied Digital's High-Performance Computing Solutions with FlexAnywhere Platform,0.1779,APLD,5.829999924,6.420000076,5.769999981,6.170000076,3182300,0,0.0,1
2023-08-22,Applied Digital Announces Elite Partner Status in NVIDIA Partner Network,0.0,APLD,6.690000057,6.940000057,5.989999771,6.139999866,5325600,0,0.0,0
2023-08-08,Applied Digital and ZEDEDA Form a Strategic Partnership to Provide New On-Demand Transmutable AI Cloud Service,0.0,APLD,7.539999962,8.18999958,7.519999981,7.579999924,4116700,0,0.0,0
2023-07-26,Northland Capital Markets Institutional Investor Conference,0.0,APLD,10.35000038,11.06999969,9.854999542,10.0,10094700,0,0.0,0
2023-07-24,Applied Digital Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results,0.0,APLD,8.199999809,9.890000343,8.116000175,8.779999733,29679600,0,0.0,0
2023-07-14,Applied Digital Onboards First Major Customer for Cloud Service,0.0,APLD,8.25,8.680000305,7.260000229,7.46999979,7559000,0,0.0,0
2023-07-11,Applied Digital Announces Promotion of Michael Maniscalco to Chief Technology Officer,0.0,APLD,8.329999924,8.732000351,8.050000191,8.43999958,4345900,0,0.0,1
2023-07-06,"Applied Digital Sets Fiscal Fourth Quarter and Full Year 2023 Earnings Conference Call for Monday, July 24, 2023 at 9:00 a.m. Eastern Time",0.0,APLD,8.800000191,8.819999695,7.0,7.699999809,19268800,0,0.0,0
2023-06-30,Applied Digital Announces Strategic Collaboration with Hewlett Packard Enterprise to Deliver AI Cloud Services,0.0,APLD,8.600000381,9.56000042,8.479999542,9.350000381,8821000,0,0.0,0
2023-06-26,5 Stocks That AI Predicts Will Double Your Money in a Year,0.0,APLD,8.819999695,9.800000191,8.140000343,9.18999958,15748900,0,0.0,0
2023-06-23,Why Applied Digital Stock Is Soaring Again Today,0.0,APLD,10.27999973,11.61999989,7.760000229,8.090000153,47975800,0,0.0,0
2023-06-12,"Applied Digital Announces Successful Integrated Systems Test at Jamestown, North Dakota Facility for HPC Deployment",0.5859,APLD,8.340000153,8.829000473,7.809999943,8.68500042,2692900,0,0.0,0
2023-05-24,Applied Digital Teams with Supermicro to Deliver AI Cloud Services,0.0,APLD,7.78000021,9.369999886,7.730000019,9.090000153,6181700,0,0.0,1
2023-05-19,Applied Digital Announces New $50 Million Loan to Accelerate Growth,0.3818,APLD,7.610000134,8.649999619,6.739999771,8.569999695,11368600,0,0.0,1
2023-05-16,Applied Digital Signs First Major Customer for Latest Artificial Intelligence Cloud Service,0.4767,APLD,4.860000134,6.25,4.349999905,6.110000134,79376400,0,0.0,1
2023-05-15,Applied Digital Launches Cloud Service to Empower Artificial Intelligence Applications,0.4767,APLD,2.980000019,3.434999943,2.970000029,3.414999962,1180300,0,0.0,0
2023-05-11,Applied Digital Announces Upcoming Conference Participation,0.0,APLD,3.670000076,3.690000057,3.450000048,3.49000001,455800,0,0.0,0
2023-05-08,Market Sentiment Around Loss-Making Applied Digital Corporation (NASDAQ:APLD),0.0,APLD,3.410000086,3.474999905,3.269999981,3.390000105,377000,0,0.0,0
2024-09-09,Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies,0.5859,KTTA,4.320000172,4.650000095,4.050000191,4.25,16600,0,0.0,1
2024-09-03,Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board,0.0,KTTA,4.559999943,4.90500021,4.559999943,4.849999905,8600,0,0.0,1
2024-08-28,Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference,0.0,KTTA,4.570000172,4.791999817,4.460000038,4.559999943,3400,0,0.0,0
2024-06-25,KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q4 2023,0.0,KTTA,4.980000019,5.300000191,4.880000114,5.300000191,4800,0,0.0,1
2024-06-13,Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial,0.7506,KTTA,5.599999905,5.698999882,5.449999809,5.698999882,9700,0,0.0,1
2024-05-28,Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting,-0.1779,KTTA,6.400000095,6.400000095,6.300000191,6.300000191,2300,0,0.0,1
2024-05-15,KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q1 2024,0.0,KTTA,6.809999943,6.890999794,6.650000095,6.650000095,1400,0,0.0,1
2024-04-29,Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting,0.2732,KTTA,6.920000076,7.032999992,6.900000095,6.920000076,1500,0,0.0,1
2024-04-24,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers",0.0,KTTA,6.900000095,6.949999809,6.800000191,6.949999809,900,0,0.0,1
2024-04-15,11 Undervalued Stocks for Less Than $50 in April 2024,0.0,KTTA,7.349999905,7.349999905,7.150000095,7.150000095,1600,0,0.0,1
2024-02-13,Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004,0.0,KTTA,6.179999828,6.449999809,6.179999828,6.449999809,3300,0,0.0,0
2024-01-08,Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position,0.7269,KTTA,7.0,7.789999962,7.0,7.352000237,10100,0,0.0,0
2024-01-02,Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients,-0.1027,KTTA,7.400000095,8.5,7.010000229,8.050000191,113400,0,0.05,1
2023-12-28,"Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023",0.0,KTTA,7.800000191,8.399999619,7.599999905,7.800000191,14875,0,0.0,0
2023-12-19,Pasithea Therapeutics Announces Results from 2023 Annual Meeting,0.0,KTTA,6.440000057,6.900000095,6.300000191,6.480000019,11220,0,0.0,1
2023-12-13,Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?,0.0,KTTA,8.300000191,9.600000381,8.0,9.140000343,48845,0,0.0,1
2023-12-11,Why Is Pasithea Therapeutics (KTTA) Stock Up 105% Today?,0.0,KTTA,16.60000038,17.39999962,7.900000095,8.840000153,4973815,0,0.0,1
2023-11-29,Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders,0.0,KTTA,6.800000191,7.800000191,6.800000191,7.079999924,37175,0,0.0,1
2023-11-09,"Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets  5 1 Integrin for the Treatment of both Sporadic and Familial ALS",0.0,KTTA,7.199999809,7.5,7.019999981,7.5,750,0,0.0,1
2023-09-14,Pasithea Therapeutics Corp. Announces Final Results of Tender Offer,0.0,KTTA,10.19999981,11.0,10.19999981,10.39999962,1640,0,0.0,0
2023-09-07,Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference,0.0,KTTA,12.5,12.5,12.18000031,12.42000008,280,0,0.0,1
2023-08-01,"Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in 5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting 5 integrin results in improved survival and motor function",0.6597,KTTA,12.19999981,12.19999981,11.60000038,12.0,21190,0,0.0,0
2023-07-31,"The Psychedelics Stock Universe Is Shrinking, Despite the Hype",0.0,KTTA,12.30000019,12.30000019,11.81999969,11.96000004,2730,0,0.0,0
2023-07-20,Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash,0.296,KTTA,11.0,12.73999977,10.60000038,11.85999966,262165,0,0.0,0
2023-07-13,"Lucy Scientific Scores Richard Nanula as CEO After Senior Roles at Disney, Amgen, Starwood",0.0,KTTA,9.100000381,9.380000114,9.020000458,9.199999809,4590,0,0.0,1
2023-06-30,Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors,0.5859,KTTA,9.300000191,9.800000191,8.720000267,9.800000191,22020,0,0.0,1
2023-06-29,Lucy Scientific Discovery Reiterates Its Proposal to Acquire Pasithea Therapeutics Corp.,0.0,KTTA,8.659999847,12.0,8.659999847,9.600000381,57690,0,0.0,1
2023-06-06,Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.,0.0,KTTA,9.800000191,9.800000191,8.840000153,9.520000458,38860,0,0.0,0
2023-06-05,Lucy Scientific Discovery Announces Proposal to Acquire Pasithea Therapeutics Corp.,0.0,KTTA,11.19999981,12.81999969,9.479999542,10.0,66040,0,0.0,0
2023-06-01,Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference,0.2732,KTTA,7.360000134,7.599999905,6.599999905,7.0,490,0,0.0,0
2023-05-03,Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference,0.0,KTTA,6.840000153,7.380000114,6.599999905,6.920000076,1035,0,0.0,0
2023-03-02,"Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting",0.0,KTTA,9.800000191,10.39999962,9.680000305,9.880000114,7050,0,0.0,0
2023-02-23,"Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)",0.0,KTTA,10.39999962,10.69999981,9.840000153,10.0,4095,0,0.0,0
2023-02-16,"Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award",0.5423,KTTA,11.39999962,12.23999977,11.11999989,11.52000046,2830,0,0.0,1
2023-01-18,Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004,0.4939,KTTA,15.19999981,15.96000004,14.39999962,14.39999962,13750,0,0.0,0
2022-12-14,Majority of Stockholders Support Pasithea Directors at Special Meeting,0.6597,KTTA,16.76000023,17.29999924,16.23999977,16.60000038,2040,0,0.0,0
2022-12-12,Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group,0.6369,KTTA,19.54000092,19.54000092,17.55999947,17.97999954,16290,0,0.0,1
2022-12-07,Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics,0.2263,KTTA,19.81999969,20.0,19.79999924,19.95999908,240,0,0.0,1
2022-12-06,Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference,0.0,KTTA,20.39999962,20.60000038,19.79999924,20.20000076,735,0,0.0,0
2022-11-28,"Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern Time",0.1531,KTTA,19.21999931,20.04000092,19.21999931,20.0,2200,0,0.0,0
2022-11-22,Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics,0.2263,KTTA,19.0,20.0,18.70000076,19.60000038,1275,0,0.0,1
2022-10-27,A New BioTech Research Race Is Focused On Improving Life For MS Patients,0.6597,KTTA,21.79999924,22.0,21.39999962,22.0,1280,0,0.0,0
2022-10-17,Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and Symposium,0.0,KTTA,25.0,25.0,18.87999916,22.20000076,16565,0,0.0,0
2022-10-14,"Pasithea' Largest Investor Group Says AlloMek Therapeutics Deal Ill-timed, Highly Dilutive",0.0,KTTA,24.60000038,25.79999924,23.0,25.0,8710,0,0.0,0
2022-10-13,Investor Group Comments on Pasithea Therapeutics Seemingly Defensive and Ill-Timed Acquisition of AlloMek Therapeutics,0.0258,KTTA,24.0,25.39999962,24.0,25.0,4410,0,0.0,0
2022-10-12,Pasithea Therapeutics Acquires AlloMek Therapeutics,0.0,KTTA,24.39999962,26.20000076,24.20000076,25.70000076,84655,0,0.0,1
2022-10-10,New Drugs And Therapies Are Giving MS And ALS Sufferers New Hope,0.2263,KTTA,25.0,25.0,23.60000038,24.79999924,4370,0,0.0,1
2022-10-03,Pasithea Therapeutics to Call Special Meeting of Stockholders,0.4019,KTTA,26.0,26.60000038,24.60000038,26.0,28050,0,0.0,0
2022-09-28,Investor Group Sends Letter to Pasithea Therapeutics Board of Directors,0.0,KTTA,24.79999924,24.79999924,23.39999962,24.0,8445,0,0.0,0
2022-09-20,Pasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to its Board of Directors,0.4939,KTTA,25.60000038,25.60000038,23.60000038,24.0,4980,0,0.0,1
2022-09-15,Pasithea Therapeutics Further Strengthens its Scientific Advisory Board with the Appointment of Dr. Merit Cudkowicz,0.7003,KTTA,23.60000038,24.39999962,23.60000038,24.0,1075,0,0.0,0
2022-09-12,Here's Why We're Not Too Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Situation,0.2235,KTTA,25.0,25.20000076,24.20000076,25.0,2530,0,0.0,0
2022-09-09,Pasithea Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference,0.0,KTTA,25.60000038,26.39999962,24.79999924,24.79999924,4140,0,0.0,0
2022-09-06,Investor Group Successful in Request to Call Special Meeting of Stockholders of Pasithea Therapeutics,0.7579,KTTA,23.0,23.57999992,22.39999962,22.79999924,7080,0,0.0,0
2022-08-24,Investor Group Urges Stockholders of Pasithea Therapeutics to Vote to Call Special Meeting,0.4019,KTTA,24.60000038,25.60000038,24.39999962,25.0,8015,0,0.0,0
2022-08-18,Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference,0.0,KTTA,24.60000038,26.60000038,24.0,26.20000076,49600,0,0.0,0
2022-08-11,Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis,0.0,KTTA,27.39999962,29.39999962,23.79999924,25.0,620030,0,0.0,0
2022-08-05,Investor Group Urges Stockholders of Pasithea Therapeutics Corp. to Call Special Meeting,0.4019,KTTA,24.39999962,25.0,24.20000076,24.79999924,4070,0,0.0,1
2022-08-02,Pasithea Therapeutics Urges Stockholders to Reject Activist Camac Groups Unjustified Campaign,-0.4019,KTTA,22.60000038,23.0,22.60000038,22.79999924,10335,0,0.0,0
2022-07-14,Pasithea Therapeutics Awarded a Drug Development Research Grant,0.6369,KTTA,20.39999962,21.60000038,19.92000008,21.0,4655,0,0.0,0
2022-06-23,Investor Group Comments on Pasithea Therapeutics Seemingly Defensive and Dilutive Related-Party Acquisition of Alpha-5,0.0258,KTTA,20.0,20.0,18.20000076,19.60000038,6145,0,0.0,1
2022-06-22,"Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC",0.0,KTTA,20.60000038,20.60000038,19.23999977,19.37999916,7440,0,0.0,0
2022-04-14,Pasithea Therapeutics to Present at the NobleCon18 Investor Conference 2022,0.0,KTTA,25.0,27.0,24.20000076,27.0,28370,0,0.0,0
2022-04-05,We're Not Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn,0.2235,KTTA,25.39999962,25.60000038,24.39999962,24.79999924,9185,0,0.0,0
2022-03-30,Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022,0.0,KTTA,27.60000038,29.39999962,27.20000076,28.0,23625,0,0.0,0
2022-03-08,Pasithea Therapeutics Announces Collaboration with The Glimpse Group,0.0,KTTA,22.0,24.79999924,21.0,24.20000076,48380,0,0.0,0
2022-02-24,Pasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022,0.0,KTTA,18.60000038,20.0,18.60000038,19.39999962,27560,0,0.0,0
2022-02-09,Pasithea Therapeutics Strengthens its Scientific Advisory Board with the Appointment of Preeminent Scientist Dr. Daniel Weinberger,0.4588,KTTA,22.39999962,24.0,22.39999962,23.79999924,23665,0,0.0,0
2022-02-03,Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple Sclerosis,0.0,KTTA,25.39999962,25.39999962,22.79999924,23.39999962,126795,0,0.0,0
2022-01-26,Pasithea Therapeutics Announces Opening of Mental Health Clinic in Los Angeles and Broadens Focus Beyond Ketamine Treatments,0.0,KTTA,24.0,25.39999962,22.79999924,23.20000076,38780,0,0.0,0
